Stories about Medikament
- 3One documentmore
Briya Expands Access to European Real-World Data Through Strategic Partnership with Casa Sollievo della Sofferenza
San Giovanni Rotondo, Italy (ots/PRNewswire) - Briya, a leading healthcare data retrieval network, is proud to announce a strategic partnership with Casa Sollievo della Sofferenza, one of Italy's premier hospitals renowned for its advanced medical care and research initiatives. This collaboration marks a significant ...
moreTOOsonix Partners with MikronMed to Introduce Innovative Dermatological Therapy in the Nordic Region
Copenhagen, Denmark (ots/PRNewswire) - A groundbreaking dermatological alliance will bring innovative dermatological treatment to the 27 million residents of the Nordic Region, offering rapid and efficient treatment for the most common skin cancer and various skin conditions - often completed in under 90 seconds. ...
moreApotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
Aachen, Germany & Toronto, Canada, (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, ...
moreCO.DON GmbH partners in EU-Funded Project to Advance 3D Bioprinting for Tissue Regeneration
Teltow (ots) - The EU-funded micro2MACRO (m2M) project, launched in December 2024, aims to advance tissue regeneration through an innovative bioprinting platform. m2M focuses on precisely patterning cell aggregates and microtissues into stable, customizable grafts that remodel into functional tissues after implantation. The project unites leading academic institutions, ...
moreX4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.
London (ots/PRNewswire) - Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare ...
more
Ancient Viral DNA Shapes Early Embryo Development
Over half of our genomes consists of thousands of remnants of ancient viral DNA, known as transposable elements, which are widespread across the tree of life. Once dismissed as the "dark side" of the genome, researchers at Helmholtz Munich and Ludwig-Maximilians-Universität (LMU) have now revealed their crucial role in early embryo development. Unanswered Questions About the Role of Ancient Viral DNA Transposable ...
moreAsklepios Kliniken GmbH & Co. KGaA
Nomination period for the Broermann Medical Innovation Award started
Gießen (ots) - - Prize money of one million euros higher than the prize money for the Nobel Prize for Medicine - Award honors researchers worldwide who have done pioneering work in medicine, biotechnology, or related fields The nomination period for the Broermann Medical Innovation Award has started. The prize, which will be awarded for the first time this year, is ...
moreBAIBYS™ Announces a Breakthrough in Fertility Treatment with a Newly CE Marked IVF System
Tel Aviv, Israel (ots/PRNewswire) - The Autonomous Sperm Selection AI-based Robotic System is Poised to Transform the IVF Market BAIBYS™, a pioneering Israeli startup in AI-powered micro-robotics for Artificial Reproductive Technology (ART), today announced it has received the CE mark for its innovative BAIBYS™ system. This milestone enables the company to ...
moreLTS Lohmann Therapie-Systeme AG
LTS wins funding from BARDA’s Patch Forward Prize Competition for two partnerships
moreSCP-Nano: A New Technology to Visualize Nanocarriers in Cells and Tissues
moreGrünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer
more
Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
London (ots/PRNewswire) - Back to media releases Next media release Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, in ...
moreRHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers
moreGerresheimer: FDA grants Tentative Approval of SQ Innovation’s Lasix® ONYU*
moreAccord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®
London (ots/PRNewswire) - - Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases. - The EC approval follows a positive opinion issued on 19 October ...
moreStrides Pharma International AG
Strides Pharma Consolidates European Business-to-Business Operations in Switzerland
moreInceptor Regulates Insulin Homeostasis: A New Approach for Diabetes Therapies
more
Technische Universität München
New method for designing artificial proteins
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Designing large new proteins with AI New method for designing artificial proteins - Efficient design of new proteins with desired properties - Size of newly designed proteins is approaching that of antibodies - Predicted protein structures successfully validated in experiments Protein design aims to create customized antibodies for therapies, biosensors for diagnostics, or ...
moreGrünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...
moreOttobock invests in NeuroTech company ONWARD® Medical
moreFirst participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...
moreEvent Announcement: VIROFIGHT Hybrid Symposium
One documentmoreEpitomee Medical to Present the Epitomee Breakthrough Oral Delivery Platform at PODD 2024 Conference
Caesarea, Israel (ots/PRNewswire) - Epitomee Medical Ltd. (TASE: EPIT) announces today that the company leadership intends to present Epitomee's Oral Delivery of Biologics Platform at the 14th Annual PODD Conference - Partnership Opportunities in Drug Delivery, taking place in Boston, MA, October 28-29, 2024. ...
more
Press Release: EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar
EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...
moreNorgine Announces Appointment of New CEO Janneke van der Kamp
London (ots/PRNewswire) - Norgine (the "Company"), a leading European specialty pharmaceutical company, has today announced the appointment of Janneke van der Kamp as its new Chief Executive Officer (CEO), effective from 1 January 2025. Current CEO, Chris Bath, has stepped down from his role effective immediately. This change in leadership will support and enhance the Company's mission of bringing transformative medicines ...
moreSuccessful MDR Certification for AI Solution in Predicting Postoperative Complications – New Product Generation for Optimized Patient Safety
Berlin (ots) - x-cardiac, a leader in AI-based medical devices for the prediction of postoperative complications after cardiac surgery, is pleased to announce the successful MDR (Medical Device Regulation) certification of its new x-cardiac-platform. This certification introduces a completely new generation of ...
moreGrünenthal appoints Dr. Jan Adams as Chief Commercial Officer
moreRHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU
moreEpitomee Medical Announces FDA Clearance of its Capsule, Weight Management Device
Caesarea, Israel (ots/PRNewswire) - Epitomee's Ingestible Capsule, Offers a Safe and Effective Prescription Solution for Adults with BMI of 25-40 looking for Alternative Drug Free Solutions for Their Weight Management Needs alongside diet and exercise. Epitomee Medical Ltd. (TASE: EPIT), announced that the United States Food and Drug Administration (FDA) has officially ...
more